Most Clicked StoriesMore >


Video: PCMA on CNBC defending the PBM industry

PCMA SmartBrief | Aug 26, 2016

Mylan is implementing a flawed tactic used among drugmakers by blaming payers for high drug prices, says Pharmaceutical Care Management Association President and CEO Mark Merritt. PBMs are hired by employers, health insurers and unions to lower drug costs. MarketWatch (08/25) CNBC (08/26) CNBC (08/25) CNNMoney (08/25) InsideHealthPolicy.com (subscription required) (08/25) Pittsburgh Post-Gazette (08/25)


Mylan's pricing strategy is common in the drug industry

PCMA SmartBrief | Aug 25, 2016

Mylan using "bait and switch" tactic with copay coupons

PCMA SmartBrief | Aug 29, 2016

Prime Therapeutics to work with Walgreens Boots Alliance

PCMA SmartBrief | Aug 29, 2016

Mylan is free to cut prices

PCMA SmartBrief | Aug 26, 2016

Mylan will continue to dominate EpiPen market with authorized generic

PCMA SmartBrief | Aug 30, 2016

Mylan to launch its own generic EpiPen

PCMA SmartBrief | Aug 29, 2016

Consumers pay one way or another for copay coupons

PCMA SmartBrief | Aug 29, 2016

Patients with diabetes struggle to afford insulin

PCMA SmartBrief | Aug 25, 2016

Drugmakers base prices on market, not R&D costs

PCMA SmartBrief | Aug 29, 2016


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more